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ABSTRACT 
 
Objective: To evaluate the effect of chemotherapy on growth and growth hormone 
(GH) secretion. 
Methods: We analyzed growth and GH secretion in 60 children in complete remission 
after treatment by chemotherapy and surgery for malignant solid tumors. None of them 
received cranial radiotherapy. Growth hormone reserve was assessed by at least two 
stimulation tests (clonidine, L-dopa, growth hormone-releasing hormone). In 12 
children the reserve of GH pretreatment was also evaluated. 
Results: Growth hormone deficiency (GHD) was observed in 27 of 60 patients (45%). 
At diagnosis, mean standing height was +0.23 ± 0.11 standard deviation score (SDS) in 
the GHD group and +0.16 ± 0.10 SDS in the non-GHD group. Alter chemotherapy, 
mean standing height in the GHD group was -0.28 ± 0.15 SDS and -0.14 ± 0.11 in the 
non-GHD group (p < 0.05), and the growth rate was +0.13 ± 0.07 SDS in the GHD 
group and +0.22 ± 0.18 SDS in the non-GHD group. For a mean follow-up of 30 
months, the mean standing height was -0.46 ± 0.29 SDS in the GHD group and -0.24 ± 
0.16 SDS for the non-GHD group (p < 0.05), and the growth rate was -0.27 ± 0.19 SDS 
in the GHD group and -0.16 ± 0.12 SDS in the non-GHD group (p < 0.05). The GH 
response to clonidine was significantly less than that found with the other stimuli. 
There was correlation between the dose intensity of some drugs and the subsequent GH 
response to stimulation tests. The GHD group was found to have received significantly 
higher doses of actinomycin D than the non-GHD group (p < 0.05). Growth impairment 
and GHD were not found to be correlated with duration of treatment and follow-up, 
tumor type, sex, or age. 
Conclusions: Chemotherapy as the sole form of treatment in children with cancer 
interferes with growth. The observed impairment of growth depends, at least in part, on 
a GHD related to chemotherapy. The growth rate in conjunction with the GH response 
to clonidine provides a sensitive measure of GHD associated with chemotherapy.  
ABBREVIATIONS 
 
AUC Area under the curve 
GH Growth hormone 
GHD Growth hormone deficiency 
GHRH Growth hormone-releasing hormona 
HT-P Hypothalamic-pituitary axis 
IGF lnsulin growth factor 
SDS Standard deviation score 
 
 
INTRODUCTION 
 
The prognosis of children with cancer has improved significantly in recent years as a 
result of new therapeutic modalities.1 Unfortunately, some of these children will have 
late effects of therapy, including those involving the endocrine system and related to 
growth. 
 
Recently we observed in a group of 25 children with osteosarcoma that chemotherapy 
used as the only form of treatment interfered with growth, probably as a result of a 
growth hormone deficiency caused by the chemotherapy.2 In this preliminary work we 
did not evaluate the pretreatment reserve of growth hormone and thus cannot Mame 
chemotherapy for the GHD observed because we cannot be certain the patients were not 
GH deficient before therapy. For this reason a prospective study was designed in which 
the reserve of GH was evaluated before and after treatment while we continued to study 
the growth and secretion of GH in a greater number of patients with different 
malignancies, who were treated with other schedules of polychemotherapy. To our 
knowledge, this is the first prospective study that analyzes both growth and GH 
secretion in children treated exclusively by chemotherapy. In addition, in the previous 
report the stimuli for GH secretion (clonidine and L-dopa) assessed the hypothalamic-
pituitary axis by acting at the hypothalamic level, which did not allow us to discern 
between possible damage to the hypothalamus, the pituitary, or both areas.2 In this 
article we study the HT-P axis by use of stimuli that act at both the hypothalamic level 
(clonidine and L-dopa) and the pituitary level (growth hormone-releasing hormone). 
Other aims of the study were the possible identification of risk factors (duration of 
treatment and follow-up, dose intensity of chemotherapy, type of tumor, sex, or age at 
diagnosis) for increased susceptibility to alterations in growth and GH secretion. 
 
 
 
METHODS 
 
Sixty consecutive children with histologically proved malignant solid tumors treated 
between the years 1984 and 1994 were induded in this study. Informed consent was 
obtained from all patients and their parents before the study. 
  
The subjects were divided into two groups. Group I (retrospective group) comprised 48 
patients (26 male subjects) who had received chemotherapy before the study. The 25 
patients with osteosarcoma previously described2 were included in this group. Mean age 
was 13.8 years (range, 4.2 to 19.8 years). The histologic type and primary location of 
the tumors of these patients were as follows: 31 cases of osteosarcoma (19 femur, 9 
tibia, 1 fíbula, 1 ulna, 1 hip), 6 cases of Ewing sarcoma [1 femur, 4 tibia, 1 clavicula], 3 
cases of rhabdomyosarcoma (1 bladder, 1 abdominal wall, 1 pelvis), 3 cases of Hodgkin 
disease, 4 cases of non-Hodgkin lymphoma; and 1 case of Wilms tumor (kidney). 
Group II (prospective group) comprised 12 patients (7 male subjects) who had not 
received chemotherapy before the study. Mean age was 12.4 years (range 4.5 to 17 
years). The histologic type and primary location of the tumors of these patients were as 
follows: 10 cases of osteosarcoma (5 femur, 4 tibia, 1 humerus), 2 cases of Ewing 
sarcoma (1 fíbula, 1 paravertebral). 
  
The treatment of these patients consisted of chemotherapy and surgery. Intraoperative 
radiotherapy over the tumoral bed was used in 60% of the cases of osteosarcoma and 
25% of the cases of Ewing sarcoma. External radiotherapy localized to the tumor site 
was used in all cases of Ewing sarcoma, Hodgkin disease, and Wilms tumor, and 33% 
of the cases of rhabdomyosarcoma. Cranial radiotherapy and intrathecal chemotherapy 
were not used in any of the cases. 
 
The chemotherapy regimen used, according to tumor type, is provided in Table I. In 14 
patients with osteosarcoma, cisplatin was administered with or totally replaced by 
carboplatin. 
 
For each patient the dose intensity of chemotherapy was calculated as the total amount 
of each drug administered per unit of body surface and per unit of time (mg/m2 per 
week) at the end of therapy. Mean duration of treatment was 11.8 ± 3.4 months. 
Chemotherapy of all patients was completed before hormonal study; the mean duration 
of this interval was 14.9 ± 1.8 months (standard error of the mean). 
  
For patients in both groups I and II, growth data at the moment of diagnosis, on 
completion of chemotherapy, and at the start of the hormonal study were obtained 
retrospectively from hospital records. Height was measured on a wall-mounted 
Harpenden stadiometer by a trained observer on each clinic visit. The height of patients 
whose primary tumor was located in the lower limbs was measured carefully, taking 
into account the length of the healthy limb. Growth velocity was calculated by height 
determinations obtained during follow-up. Four patients who had received radiotherapy 
to the vertebral column were excluded from the auxologic study. 
 
Data were compared with the growth standards of Tanner et al.3 Results were reported 
as standard deviation scores (SDS = [a-ā]:SD) to allow for comparison of patients of 
different sex and age.  
 
Pubertal status was assessed clinically by the method of Tanner.4 Testicular volumes 
were estimated by comparison with the Prader orchidometer.5 Bone age was evaluated 
according to the Tanner-Whitehouse 2 method.6 Nine girls with bone age greater than 
14 years and 9 boys with bone age greater than 16 years were excluded from auxologic 
evaluation. 
 
For all patients (groups I and II), after a posttreatment interval we assessed the GH 
response to at least two of the following stimuli: clonidine (0.15 mg/m2 orally, L-dopa 
(300 mg/m2 orally), and GHRH (1-2 µg/kg intravenously). Each stimulation test was 
performed at 8 AM on different days. The combination of clonidine and L-dopa was 
given to 22 patients, clonidine and GHRH to 32 patients, and clonidine, L-dopa, and 
GHRH to 6 patients. Growth hormone deficiency was diagnosed as a failure to achieve 
a peak GH response of 10 ng/ml to at least one of the provocative tests. We determined 
the area under the curve for all patients on the basis of the values obtained in the 
provocative tests. The AUC was calculated with the trapezoidal solution. All patients 
were also tested for basal insulinlike growth factor I levels. Growth hormone levels 
were measured by means of a double-monoclonal immunoradiometric assay with a 
detection limit of 0.1 ng/ml (human growth hormone “COATRIA”, Biomérieux, Marcy 
l'Etoile, France). Intraassay variation was 5.2% to 2.1% at GH levels between 1.05 and 
43.5 ng/ml. Interassay variation was 6% at a GH level of 1.1 ng/ml and 3.7% at 41.8 
ng/ml. AH samples from one child were measured in the same assay, and all samples 
were measured in duplicate. The IGF-I levels were also measured with a double-
monoclonal immunoradiometric assay with a detection limit of 0.001 U/ml (Diagnostic 
Systems Laboratories Inc., Webster, Tex.). The assay was performed after an acid 
extraction step in which IGF-I is separated from its binding protein in serum. Intraassay 
variation was 7.2% to 4.9% at IGF-I levels between 0.07 and 0.65 U/rnl. Interassay 
variation was 7.1% at an IGF-I level of 0.02 U/ml and 10.1% at 0.35 U/ml. All samples 
from one child were measured in the same assay, and all samples were measured in 
duplicate. 
 
For all patients in group II the same hormonal study as described aboye was undertaken 
before the start of treatment for cancer. For these pretreatment tests, all patients were 
given clonidine and GHRH as stimuli to GH release. 
 
 
Statistical Analysis 
 
Results are expressed as mean ± SD unless otherwise noted. Comparisons between 
groups were analyzed by the Wilcoxon rank-sum test. Chi-square test was used to 
compare the differences in the distribution of the patients characteristics. The p values 
for all tests are two tailed. Correlation was assessed with simple and multiple linear 
regression. A p value of less than 0.05 was considered statistically significant. Data 
from this investigation were analyzed with the SPSS program for Windows, version 6.0 
(SPSS Inc., Chicago, Ill.) and BMDP Dynamic ver-sion 7.0 (Cork, Ireland) packages. 
 
 
RESULTS 
 
Auxologic Study 
 
Data from both the prospective and retrospective groups was pooled because all 
anthropometric data were available for all patients in both groups at diagnosis, at the 
end of treatment, and when the study was performed. 
 
When analyzed in terms of height percentiles, the data demonstrate a statistically 
significant reduction in the height percentiles of patients during treatment (p < 0.05). 
The reduction in the height percentiles was even more significant during the 
posttreatment interval (p < 0.01) (Figure). 
 
When analyzed in terms of SDS, the data demonstrated a statistically significant relative 
reduction in height during treatment (0.19 ± 0.10 vs -0.21 ± 0.14 SDS, p < 0.05); this 
reduction continued throughout the posttreatment interval. For a mean follow-up of 30 ± 
4 months from the end of treatment, we again observed a statistically significant 
reduction (p < 0.05) in height and growth rate with respect to that at the end of 
treatment (-0.21 ± 0.14 vs -0.35 ± 0.23 SDS and 0.18 ± 0.13 vs -0.22 ± 0.15 SDS, 
respectively).  
 
Hormonal Study 
 
Prospective goup 
All patients had adequate pretreatment response of GH. The GH response before and 
after treatment and the statistical analysis of the data are listed in Table II. The 
percentage of patients who had an adequate GH response after stimulation (percentage 
of response) with clonidine or GHRH before treatment was significantly higher than 
that obtained after treatment (73% vs 8% and 91% vs 42%, respectively; p < 0.001 for 
both stimuli). All the patients had normal serum levels of IGF-I before treatment; three 
patients had subnormal levels of IGF-I after treatment. 
 
Prospective and retrospective groups 
Data from both the prospective and retrospective groups were pooled to investigate the 
relationship between the results of the study of the HT-P axis and other variables such 
as dose intensity of chemotherapy administered, duration of treatment, duration of the 
posttreatment interval, age, sex, and so on. 
 
For 45% of all patients (20 cases of osteosarcoma and 7 nonosteosarcoma), the GH 
response after stimulation was subnormal. A comparative statistical analysis of GH 
response in GH-deficient and non-GH-deficient patients according to stimulus used is 
given in Table III. 
 
In 20 of the 60 patients the serum IGFI level was below the normal range; 12 of the 20 
patients were GH deficient, and 8 were not GH deficient. 
  
In 9 patients bone age was retarded 1 year or more in comparison with the Tanner-
Whitehouse standards; 5 of these patients were GH deficient and 4 were not. Bone age 
ranged from retarded 33 months to advanced 2 months. 
 
Pubertal development was within the normal range for all patients. All girls at Tanner 
stages 3 and 4 had experienced menarche with mean age at menarche of 12.4 years. 
Boys had testicular volume in accordance with their pubertal stage and there was 
normal development of secondary sexual characteristics in older patients. 
 
 
Relationships Between Auxologie and Hormonal Studies 
 
We looked for a correlation between auxologic and hormonal data in the GHD and the 
non-GHD groups. At diagnosis, mean standing height was +0.23 ± 0.11 SDS in the 
GHD group and +0.16 ± 0.10 SDS in the non-GHD group. At the end of treatment, 
mean standing height was —0.28 ± 0.15 SDS in the GHD group and —0.14 ± 0.11 SDS 
in the non-GHD group (p < 0.05). For a mean follow-up period of 30 months from the 
end of treatment, the mean standing height was —0.46 -± 0.29 SDS in the GHD group 
and —0.24 ± 0.16 SDS in the non-GHD group (p < 0.05). Growth rate at the end of 
treatment was +0.13 ± 0.07 SDS in the GHD group and +0.22 ± 0.18 SDS in the non-
GHD group. For a mean follow-up period of 30 months from the end of treatment, 
growth rate was significantly different between the GHD and the non-GHD groups       
(-0.27 ± 0.19 vs —0.16 ± 0.12 SDS, p < 0.05) (Table IV). 
 
 
Relationships Between Oncologic/Auxologic Hormonal Data 
 
There was no relationship between duration of treatment, duration of posttreatment 
interval, type of tumor, dose intensity of chemotherapy, sex, or age at diagnosis and 
either of the auxologic parameters (height and growth rate). There was no relationship 
found between duration of treatment, duration of posttreatment interval, type of tumor, 
sex, or age at diagnosis and the existence or absence of GHD. There was a tendency 
toward a greater incidence of GHD in patients who received chemotherapy at a younger 
age, although this was not statistically significant (p = 0.07). However, a significant 
correlation was observed between age at diagnosis and maximum peak and AUC of GH 
after stimulation with L-dopa (p = 0.01 and p = 0.02, respectively). 
 
There was a statistically significant rela-tionship between existence of GHD and dose 
intensity of actinomycin D (p < 0.05). No relationship was observed between GHD and 
the dose intensity of other chemotherapeutic agents. There was a significant correlation 
between dose intensity of carboplatin and maximum peak and AUC of GH after 
stimulation with clonidine (p = 0.02 and p = 0.03, respectively). Statistically significant 
correlation between dose intensity of actino-mycin D and maximum peak and AUC of 
GH after stimulation with L-dopa was also observed (p = 0.04). 
  
 
  
DISCUSSION 
 
Chemotherapy and Growth 
 
The influence of chemotherapy, when used as the only form of treatment for cancer, on 
growth is poorly understood and has been studied in patients with hematologic 
neoplasms (leukemia or lymphoma). Furthermore, the issue has almost always been 
approached indirectly because, in the majority of cases, chemotherapy is an integral part 
of a combined treatment program with radiotherapy,7-22 and for this reason the results of 
such studies are not entirely comparable with ours. These studies attribute a negative 
influence of chemotherapy on growth on the basis of the following observations: 
patients treated with longer or more intensive courses of chemotherapy exhibit less 
growth than those treated with shorter or less intense regimens,10,15,16,18 and patients 
treated with both radiotherapy and chemotherapy have less growth than those treated 
exclusively with radiotherapy.17 
 
In most of these studies, an influence of chemotherapy on growth parameters 
(height/growth rate) was observed, whether as a reduction in the growth rate during 
chemotherapy followed by catchup growth9, 12-14, 20-22 or in a "chronic" form with absent 
or reduced subsequent recovery. 7, 10, 15-18 Some studies have found no significant 
influence of chemotherapy on grovvth.8, 11, 19 It is probable that differences in drug 
regimens may account for reported variations in the incidence and severity of growth 
retardation in patients treated with chemotherapy12, 13, 20 
 
In our study, as in some others,12 growth parameters (height/growth rate) were not 
correlated with duration of treatment or intensity of chemotherapy. However, some 
authors have indeed observed such correlation.15, 16, 18 We did not observe relationships 
between duration of follow-up, type of tumor, sex, age at diagnosis, and above-
mentioned parameters. Other authors have observed greater growth impairments in the 
youngest patients10,18 and in girls.18 
 
 
Chemotherapy and Seeretion of Growth Hormone 
 
Given the previously demonstrated negative influence of chemotherapy on growth and 
having eliminated the most common causes of short stature in the child population 
(malabsorption syndromes, infections, diseases of the kidney, liver, blood), we decided 
to look for a hormonal explanation. 
 
The only studies of GH secretion in children treated exclusively with chemotherapy are 
limited to hematologic neoplasms,19, 23, 24 and more recently to children who received 
chemotherapy without total body irradiation in preparation for bone marrow 
transplantation as treatment for hematologic neoplasms and other nontumoral illnesses 
(aplastic anemia, immunodeficiency syndromes, and so on).19, 25-27 The majority, but not 
all, of these studies found that chemotherapy did not affect GH secretion. Voorhess et 
at.23 found subnormal response of GH after stimulation with arginine and insulin in 5 of 
60 patients who had been treated with chemotherapy for acute lymphoblastic leukemia 
although these patients had also received intrathecal methotrexate therapy as 
prophylaxis for the central nervous system. 
  
According to the results of our prospective study, chemotherapy used as the only form 
of treatment in children with cancer significantly diminishes secretion of GH provoking 
GHD in a significant percentage of patients. 
 
Neither sex nor age at diagnosis represented risk factors for GHD in our patients, 
although we did observe a tendency toward a greater incidence of GHD in patients who 
received chemotherapy at a younger age. Kirk et al.10 observed an in-crease in the 
incidence of GHD in boys relative to girls. 
 
The posttreatment levels of IGF-I were diminished in 20 of the 60 (33%) children in our 
study. In this respect our results coincide with those of other studies2,16,19 and 
corroborate the theory suggested by some authors28,29 that chemotherapy reduces IGF-I 
concentrations in the circula-tion. This theory is further supported by Thun-Hohenstein 
et al.,16 who reported that 75% of the cases of IGF-I deficit in their study were 
associated with patients who had received more intensive chemotherapy. As suggested 
by Rappaport and Brauner28 and supported by Berry et al.,9 it would not be surprising to 
find that plasma concentrations of IGF-I decrease during chemotherapy. In our study we 
did not measure IGF-I levels during or immediately after treatment and thus do not 
know how these levels changed over time. Malnutrifion may also contribute to reduced 
IGF-I levels in both groups. Another possibility in the non-GHD group is the 
development of a GH neurosecretory dysfunction, which would explain the coexistente 
of normal GH response to stimulation, poor growth in many patients, and low IGF-I 
values.2 Increased levels of IGF-I were not detected in any of our patients; this finding 
suggests that resistance or an altered sensitivity of tissue receptors to growth factors 
does not develop in patients treated by chemotherapy.24
 
 
Physiopathology of Growth Impairment after Chemotherapy 
 
The mechanism by which chemotherapy interferes with growth is not fully un-derstood. 
A reduction in the growth rate of children during oncologic treatment is a predictable 
and well-demonstrated fact.9,12-15,18,21,24 Various explanations have been proposed 
including (1) the disease process itself, (2) an increase in nutritive requirements, (3) 
malnutrition during treatment, (4) infections, (5) vomiting, (6) the treatment 
(chemotherapy, radiothera-py, corticoids) and, (7) combinations of the aboye factors. 
However, a persistent reduction in growth rate after cessation of chemotherapy is 
difficult to explain2,10,15-18 except in cases in which the tumor or the treatment produce 
or provoke important late effects. Studies to date attribute this persistent reduction in 
growth rate to (1) prolonged treatment with corticoids, (2) radiotherapy/chemo-therapy 
synergism, (3) GHD as a result of cranial radiotherapy, (4) intensity and duration of 
chemotherapy, or (5) reduced peripheral tissue response to growth factors.* 
 
On the basis of the results of our prospecfive study, we suggest that GHD related to 
chemotherapy should be considered as a further cause of persistent re-duction in growth 
rate, especially because we have demonstrated that patients with GHD grow 
significantly less than those without GHD. Other authors have found a similar 
relationship between reduced growth and GHD,7 although still others have found no 
such relationship.16, 23 Furthermore, in corroboration with Kirk et al,10 we did not detect 
GHD in all patients with growth impairment. 
 
The GHD could be related to a toxic effect of chemotherapy on the HT-P axis, 
especially in drugs such as carboplatin that are known to cross the blood-brain barrier.31 
We believe that this possible selective toxic effect of chemotherapy on the HT-P axis is 
related more to individual susceptibility than the other parameters, given that, as we 
have pointed out, we did not find any relationship between GHD and either duration of 
treatment or duration of posttreatment interval. Furthermore, there is no apparent 
relationship between cumulative dose of “toxin” and toxic effect except that related to 
carboplatin and actinomycin-D. In this respect our results coincide with those of other 
authors.16 
 
Clonidine and L-dopa stimulate GH secretion by acting at the hypothalamic level.32-34 
L-Dopa, like exogenous GHRH, also stimulates GH secretion by acting at the pituitary 
level.35 
 
Given the mechanisms of stimulation of GH secretion, we might hypothesize that 
chemotherapy damages the pituitary. This hypothesis is supported by the reduced 
posttreatment response to clonidine and GHRH in the prospective group. Alternatively, 
chemotherapy might damage the hypothalamus, which is supported by the fact that in 
the prospective group the most pronounced reduction in response to stimulation 
occurred with clonidine (Table II). Similarly, in the non-GHD group the GH response 
(maximum peak and AUC) was smaller after stimulation with clonidine than after 
stimulation with GHRH and L-dopa (Table III). Damage to the hypothalamus is further 
suggested by the fact that in the GHD groups the reduction in response to clonidine in 
ternas of AUC was relatively greater than the reduction in response to L-dopa and 
especially GHRH (Table III). 
 
The possibility of functional somatotroph cell impairment related to preexisting 
hypothalamic dysfunction in the cause of GHD also needs to be considered, because a 
reduced GH response to GHRH was found in the group with GHD. However, direct 
pituitary Damage, which might be related to a certain cytostatic dose or individual 
tolerance to chemotherapy, cannot be ruled out. 
 
The fact that some patients without GHD patients had reduced growth rate with 
subsequent recovery could indicate that some patients have a transient functional 
impairment as a result of chernatherapy but later recover. 
 
The alterations resulting from chemotherapy in the secretion of GH appear to be similar 
to those resulting from cranial radiotherapy, which is known to cause a primary lesion 
in the hypothalamus.28,36 As could be the case with chemotherapy, high doses of 
radiotherapy produce an effect in both the hypothalamus and the pituitary.28 
 
We conclude that chemotherapy at high doses, when used in children as the only form 
of treatment for cancer, interferes with growth during and after treatment. Furthermore, 
such chemotherapy when used in children as the only form of treatment for cancer 
provokes GHD. Given that patients with GHD grow significantly less than those 
without GHD, we believe that the observed impairment of growth of these children 
depends, at least in part, on a GHD. This GHD resulting from chemotherapy could be 
related to an alteration in the hypothalamus, although it is not possible to rule out an 
alteration in the pituitary. In this study we found no factors related to treatment 
(duration of treatment, duration of posttreatment interval), oncology (type of tumor), or 
demographics (sex, age at diagnosis) that would allow prediction of the appearance of a 
GHD or an impairment of growth. Individual susceptibility and the dose intensity of 
some drugs probably explain the appearance of these alterations in certain patients. 
Finally, given that the GH response to clonidine in the non-GHD group was markedly 
reduced relative to the response to the other stimuli, we believe that a diminished 
growth rate in conjunction with a reduced response to clonidine is a sensitive measure 
of GHD associated with chemotherapy. These measurements should be taken in the 
follow-up of patients for the detection of any alteration in growth so that treatment can 
be considered as soon as possible. 
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Table 1. Main chemotherapeutic agents used for each type of tumor 
 
Tumor ADR Act-D Ara-C Bleo CDDP CPA DXM DTIC IFX MTX
Ewing sarcoma + + – + – + – – + + 
Hodgkin disease + – – + – – – + – – 
Non-Hodgkin disease + – + + + + + – + + 
Osteosarcoma + + – + + + – – – + 
Rhabdomyosarcoma + + – – + + – + + – 
Wilms tumor + + – – + + – – + – 
Act-D, Actinomycin D; ADR, adriamycin; Ara-C, cytarabine; Bleo, bleomycin; CDDP, cisplatin; 
CPA, cyclophosphamide; DXM, dexamethasone; IFX, ifosfamide,;MTX, methotrexate; 
 
 
 
Tumor Nitrog M. Pred Procarb Vinbl VCR VP-16 
Ewing sarcoma – – – – + – 
Hodgkin disease + + + + + – 
Non-Hodgkin disease – + – – + + 
Osteosarcoma – – – – + – 
Rhabdomyosarcoma – – – – + – 
Wilms tumor – – – – + – 
Nitrog M, nitrogen mustard; Pred, prednisone; Procarb, procarbanize;             
VCR, vincristine;Vinbl, vinblastine,VP-16, etoposide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Maximum peak and AUC of GH response to clonidine and GHRH in the prospective group 
(comparative statistical analysis) 
Patient Nº Peak AUC Peak AUC Peak AUC Peak AUC 
1 11.0 98.2 21.0 209.8 1.1 12.4 5.6 52.2 
2 4.5 40.1 13.3 122.8 3.7 22.0 2.2 22.5 
3 6.1 45.4 13.1 63.0 6.3 32.3 4.1 41.0 
4 ND ND 12.8 82.8 1.8 14.1 2.6 23.4 
5 32.0 200.7 5.2 46.9 7.8 55.0 5.9 58.8 
6 12.2 95.8 18.3 184.0 3.8 11.2 8.0 85.6 
7 10.2 75.1 10.7 53.4 7.2 56.3 11.2 41.3 
8 17.5 130.4 ND ND 3.7 29.5 16.7 151.2 
9 10.5 79.5 11.6 79.8 9.0 57.0 10.1 78.0 
10 5.2 31.6 10.5 87.2 4.3 47.5 2.4 27.0 
11 12.1 88.6 12.4 97.3 2.6 20.2 10.9 34.0 
12 16.9 109.6 12.1 85.9 16.2 81.2 15.9 136.9 
Mean+SD 12.6±7.7 90.4±47.5 12.8±4.1 101.1±52.0 5.6±4.1* 36.5±22.4* 7.9±4.9† 62.6±43.1†
AUC, Area under curve (in nanograms per milliliter per 120 minutes); GH, growth hormone; GHRH, 
growth hormone-releasing hormone; peak, maximum peak (in nanograms per milliliter); ND, not done. 
*p<0.01 after treatment versus before treatment. 
†p<0.05 after treatment versus before treatment. 
   
 
 
 
Table 3. Comparative statistical analysis of measures of GH response alter stimulus 
with clonidine, L-dopa, and GHRH in GH-deficient and non-GH-deficient patients 
 Clonidine L-Dopa GHRH 
Non-GHD    
Peak (ng/ml) 7.4±4.3 16.3±8.8‡ 16.4±7.2‡
AUC (nc/ml/120 min) 55.4±33.2 11.93±76.3‡ 129.8±65.4‡
Response (%) 27 84‡ 96 
GHD    
Peak (ng/ml) 3.9±2.1 4.6±2.2§ 4.9±2.3§
AUC (nc/ml/120 min) 26.4±15.1 38.9±21.2* 45.0±21.5†
Response (%) 0 0§ 0§
Values (except percentage of response) are expressed as mean ± SD. 
AUC, Area under curve (in nanograms per milliliter per 120 minutes); GH, growth 
hormone; GHRH, growth hormone-releasing hormone; peak, maximum peak. 
*p<0.05 compared with clonidine. 
†p<0.01 compared with clonidine. 
‡p<0.001 compared with clonidine. 
§Not significant compared with clonidine. 
 
 
 
Table 4. Height and growth rate in GH-deficient and non-GH-deficient patients 
Time of measurement  Height SDS p Growth rate SDS p 
Diagnosis     
GHD group 0.23 ± 0.11    
Non-GHD group 0.16 ± 010    
End of therapy     
GHD group -0.28 ± 0.15 0.04 0.13 ± 0.07  
Non-GHD group -0.14 ± 0.11  0.22 ± 0.18  
30 Months' follow-up     
GHD group -0.4 ± 0.29 0.03 (0.02)* -0.27 ± 0.19 0.03 
Non-GHD group -0.24 ± 0.16  -0.16 ± 0.12  
Values (except p value) are expressed as mean ± SD. 
GH, Growth hormone; GHD, growth hormone deficiency; SDS, standard deviation 
score. 
*Differences between diagnosis and follow-up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. Evolution of height percentiles (excluding patients with adult bone age and 
those who received radiotherapy to the spinal column) at diagnosis, end of treatment, 
and hormonal study performance (n = 39). Height P, Height percentile. *p < 0.05;     
**p < 0.01. 
 
 
 
 
